Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 15;1:16012. doi: 10.1038/npjvaccines.2016.12

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Immunogenicity and protective efficacy of CysVac2 across different MHC haplotypes. BALB/c (n=6) or Q(s) mice (n=6) were vaccinated s.c. with BCG, or three times with CysVac2 formulated in MPL/DDA. Twelve weeks after the first vaccination, the mice were challenged with ~100 CFU of M. tuberculosis by aerosol route and 4 weeks later they were killed and the bacterial load assessed in the lung. The data are presented as Log₁₀ of the mean of CFU±s.e.m. (a, b). The frequency of CysVac2-specific CD4⁺ T cells producing IFN-γ, IL-2 or TNF (c, e) or IL-17 (d, f) was determined in lung cells stimulated ex vivo with CysVac2 protein in the presence of brefaldin A. The significance of differences between groups was determined by one- or two-way analysis of variance (ANOVA) (NS=not significant; *P<0.05; **P<0.01; ***P<0.0001).